# APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

> **NCT04214860** · PHASE1 · COMPLETED · sponsor: **Aprea Therapeutics** · enrollment: 51 (actual)

## Conditions studied

- Myeloid Malignancy

## Interventions

- **DRUG:** APR-246
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT04214860
- **Lead sponsor:** Aprea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-13
- **Primary completion:** 2022-01-14
- **Final completion:** 2022-01-14
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04214860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04214860, "APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04214860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*